{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:51:40Z","timestamp":1791661900103,"version":"4.3.4"},"reference-count":107,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK 20230103"],"award-info":[{"award-number":["BK 20230103"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82522079"],"award-info":[{"award-number":["82522079"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173741"],"award-info":[{"award-number":["82173741"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.drudis.2026.104819","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:44:11Z","timestamp":1790811851000},"page":"104819","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Agonist-informed antagonist discovery: Discovery approaches, medicinal chemistry insights, and design boundaries"],"prefix":"10.1016","volume":"31","author":[{"given":"Bojia","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0978-7043","authenticated-orcid":false,"given":"Caiyiren","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qidong","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8181-5644","authenticated-orcid":false,"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104819_b0005","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1248\/bpb.b22-00143","article-title":"Pharmacology of antagonism of GPCR","volume":"45","author":"Kurose","year":"2022","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.drudis.2026.104819_b0010","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1096\/fj.00-0438rev","article-title":"Inverse, protean, and ligand-selective agonism: matters of receptor conformation","volume":"15","author":"Kenakin","year":"2001","journal-title":"FASEB J"},{"key":"10.1016\/j.drudis.2026.104819_b0015","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1021\/acs.jmedchem.5b00982","article-title":"Tactical approaches to interconverting GPCR agonists and antagonists","volume":"59","author":"Dosa","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104819_b0020","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1476-5381.1968.tb00444.x","article-title":"Selective blockade of adrenoceptive beta receptors in the heart","volume":"32","author":"Dunlop","year":"1968","journal-title":"Br J Pharmacol Chemother"},{"key":"10.1016\/j.drudis.2026.104819_b0025","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1021\/jm00163a036","article-title":"Synthesis and beta-adrenergic antagonist activity of stereoisomeric practolol and propranolol derivatives","volume":"33","author":"Leftheris","year":"1990","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104819_b0030","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1001\/jama.1971.03180260050019","article-title":"Naloxone treatment of opiate dependence. A progress report","volume":"215","author":"Zaks","year":"1971","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2026.104819_b0035","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1073\/pnas.73.11.4215","article-title":"The opiate receptor: a model explaining structure-activity relationships of opiate agonists and antagonists","volume":"73","author":"Feinberg","year":"1976","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2026.104819_b0040","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/00004836-199410000-00017","article-title":"The development of cimetidine: 1964\u20131976. A human story","volume":"19","author":"Molinder","year":"1994","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.drudis.2026.104819_b0045","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/978-1-4939-7465-8_12","article-title":"Approaches for differentiation and interconverting GPCR agonists and antagonists","volume":"1705","author":"Miszta","year":"2018","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.drudis.2026.104819_b0050","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s43556-023-00156-w","article-title":"Structure, function and drug discovery of GPCR signaling","volume":"4","author":"Cheng","year":"2023","journal-title":"Mol Biomed"},{"key":"10.1016\/j.drudis.2026.104819_b0055","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev.physiol.66.032802.154710","article-title":"Ligand control of coregulator recruitment to nuclear receptors","volume":"67","author":"Nettles","year":"2005","journal-title":"Annu Rev Physiol"},{"issue":"3","key":"10.1016\/j.drudis.2026.104819_b0060","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1152\/physrev.00022.2021","article-title":"Mechanisms and physiological implications of cooperative gating of clustered ion channels","volume":"102","author":"Dixon","year":"2022","journal-title":"Physiol Rev"},{"key":"10.1016\/j.drudis.2026.104819_b0065","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/39807","article-title":"The capsaicin receptor: a heat-activated ion channel in the pain pathway","volume":"389","author":"Caterina","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104819_b0070","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.neuron.2018.02.022","article-title":"Regulation of body temperature by the nervous system","volume":"98","author":"Tan","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.drudis.2026.104819_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107474","article-title":"Hyperthermia induced by transient receptor potential vanilloid-1 (TRPV1) antagonists in human clinical trials: insights from mathematical modeling and meta-analysis","volume":"208","author":"Garami","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104819_b0080","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1523\/JNEUROSCI.5150-09.2010","article-title":"Contributions of different modes of TRPV1 activation to TRPV1 antagonist-induced hyperthermia","volume":"30","author":"Garami","year":"2010","journal-title":"J Neurosci"},{"key":"10.1016\/j.drudis.2026.104819_b0085","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1021\/acs.jmedchem.0c00982","article-title":"Discovery of benzopyridone-based transient receptor potential vanilloid 1 agonists and antagonists and the structural elucidation of their activity shift","volume":"64","author":"Thorat","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104819_b0090","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/23328940.2015.1048928","article-title":"Effect of capsaicin on thermoregulation: an update with new aspects","volume":"2","author":"Szolcs\u00e1nyi","year":"2015","journal-title":"Temperature (Austin)"},{"key":"10.1016\/j.drudis.2026.104819_b0095","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/7854_2022_326","article-title":"Dopamine D3 receptor, cognition and cognitive dysfunctions in neuropsychiatric disorders: from the bench to the bedside","volume":"60","author":"Torrisi","year":"2023","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.drudis.2026.104819_b0100","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/biom11010104","article-title":"Neuronal dopamine D3 receptors: translational implications for preclinical research and CNS disorders","volume":"11","author":"Kiss","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.drudis.2026.104819_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129654","article-title":"2-Phenylcyclopropylmethylamine (PCPMA) as a privileged scaffold for central nervous system drug design","volume":"101","author":"Li","year":"2024","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104819_b0110","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1021\/jm5019274","article-title":"Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents","volume":"58","author":"Cheng","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104819_b0115","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1021\/jm801354e","article-title":"Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action","volume":"52","author":"Cho","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104819_b0120","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1021\/acs.jmedchem.9b01835","article-title":"Design and synthesis of bitopic 2-phenylcyclopropylmethylamine (PCPMA) derivatives as selective dopamine D3 receptor ligands","volume":"63","author":"Tan","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104819_b0125","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1021\/acs.jmedchem.8b00836","article-title":"Aminergic GPCR-ligand interactions: a chemical and structural map of receptor mutation data","volume":"62","author":"Vass","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104819_b0130","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1021\/acs.jmedchem.9b01105","article-title":"2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing bivalent or bitopic molecules for G-protein coupled receptors. The whole is greater than the sum of its parts","volume":"63","author":"Newman","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104819_b0135","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.cell.2018.01.001","article-title":"5-HT(2C) receptor structures reveal the structural basis of GPCR polypharmacology","volume":"172","author":"Peng","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2026.104819_b0140","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1021\/acs.jcim.3c00732","article-title":"A novel \u201cactivation switch\u201d motif common to all aminergic receptors","volume":"63","author":"Lee","year":"2023","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.drudis.2026.104819_b0145","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1248\/yakushi.24-00141","article-title":"Novel regulatory mechanisms for expression of drug metabolism-related factors","volume":"144","author":"Nakano","year":"2024","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.drudis.2026.104819_b0150","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.959902","article-title":"The role of pregnane X receptor (PXR) in substance metabolism","volume":"13","author":"Lv","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.drudis.2026.104819_b0155","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/03602532.2024.2366948","article-title":"Advances in drug resistance of osteosarcoma caused by pregnane X receptor","volume":"56","author":"Mao","year":"2024","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.drudis.2026.104819_b0160","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/med.21648","article-title":"Strategies for developing pregnane X receptor antagonists: implications from metabolism to cancer","volume":"40","author":"Chai","year":"2020","journal-title":"Med Res Rev"},{"key":"10.1016\/j.drudis.2026.104819_b0165","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41467-017-00780-5","article-title":"SPA70 is a potent antagonist of human pregnane X receptor","volume":"8","author":"Lin","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104819_b0170","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1021\/acs.jmedchem.0c02201","article-title":"Building a chemical toolbox for human pregnane X receptor research: discovery of agonists, inverse agonists, and antagonists among analogs based on the unique chemical scaffold of SPA70","volume":"64","author":"Li","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104819_b0175","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.1021\/acs.jmedchem.0c02245","article-title":"Designing out PXR activity on drug discovery projects: a review of structure-based methods, empirical and computational approaches","volume":"64","author":"Hall","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104819_b0180","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1038\/s41467-024-48472-1","article-title":"Chemical manipulation of an activation\/inhibition switch in the nuclear receptor PXR","volume":"15","author":"Garcia-Maldonado","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104819_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154338","article-title":"The role of peroxisome proliferator-activated receptors (PPAR) in immune responses","volume":"114","author":"Christofides","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.drudis.2026.104819_b0190","doi-asserted-by":"crossref","first-page":"e00601","DOI":"10.1128\/MCB.00601-18","article-title":"Transcriptional and epigenomic regulation of adipogenesis","volume":"39","author":"Lee","year":"2019","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.drudis.2026.104819_b0195","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41569-021-00569-6","article-title":"PPAR control of metabolism and cardiovascular functions","volume":"18","author":"Montaigne","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.drudis.2026.104819_b0200","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev.biochem.77.061307.091829","article-title":"Fat and beyond: the diverse biology of PPAR\u03b3","volume":"77","author":"Tontonoz","year":"2008","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.drudis.2026.104819_b0205","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1210\/me.2005-0171","article-title":"A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPAR\u03b3) recruits PPAR\u03b3-coactivator-1\u03b1, prevents triglyceride accumulation, and potentiates insulin signaling in vitro","volume":"20","author":"Burgermeister","year":"2006","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.drudis.2026.104819_b0210","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.bmc.2013.02.003","article-title":"Design and synthesis of a series of \u03b1-benzyl phenylpropanoic acid-type peroxisome proliferator-activated receptor (PPAR) gamma partial agonists with improved aqueous solubility","volume":"21","author":"Ohashi","year":"2013","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2026.104819_b0215","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.3390\/ijms24043940","article-title":"Structural biology inspired development of a series of human peroxisome proliferator-activated receptor gamma (PPAR\u03b3) ligands: from agonist to antagonist","volume":"24","author":"Miyachi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104819_b0220","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1124\/mol.107.041202","article-title":"The differential interactions of peroxisome proliferator-activated receptor gamma ligands with Tyr473 is a physical basis for their unique biological activities","volume":"73","author":"Einstein","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.drudis.2026.104819_b0225","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.str.2007.07.014","article-title":"Partial agonists activate PPAR\u03b3 using a helix 12 independent mechanism","volume":"15","author":"Bruning","year":"2007","journal-title":"Structure"},{"key":"10.1016\/j.drudis.2026.104819_b0230","doi-asserted-by":"crossref","first-page":"5080","DOI":"10.1016\/j.bmc.2005.03.027","article-title":"Nuclear receptor antagonists designed based on the helix-folding inhibition hypothesis","volume":"13","author":"Hashimoto","year":"2005","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2026.104819_b0235","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1016\/j.bmcl.2015.05.025","article-title":"Peroxisome proliferator-activated receptor gamma (PPAR\u03b3) has multiple binding points that accommodate ligands in various conformations: Structurally similar PPAR\u03b3 partial agonists bind to PPAR\u03b3 LBD in different conformations","volume":"25","author":"Ohashi","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104819_b0240","doi-asserted-by":"crossref","first-page":"9223","DOI":"10.3390\/ijms22179223","article-title":"Structural biology-based exploration of subtype-selective agonists for peroxisome proliferator-activated receptors","volume":"22","author":"Miyachi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104819_b0245","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.3390\/biom12111614","article-title":"Molecular modeling of allosteric site of isoform-specific inhibition of the peroxisome proliferator-activated receptor PPAR\u03b3","volume":"12","author":"Almahmoud","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.drudis.2026.104819_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128676","article-title":"Arylalkynyl amide-type peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3)-selective antagonists covalently bind to the PPAR\u03b3 ligand binding domain with a unique binding mode","volume":"64","author":"Yoshizawa","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104819_b0255","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1126\/science.6189183","article-title":"Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)","volume":"220","author":"Barr\u00e9-Sinoussi","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104819_b0260","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/466S1a","article-title":"HIV\/AIDS","volume":"466","author":"Mandavilli","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104819_b0265","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.tim.2019.06.002","article-title":"Molecular mechanism of HIV-1 entry","volume":"27","author":"Chen","year":"2019","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.drudis.2026.104819_b0270","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/384179a0","article-title":"CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5","volume":"384","author":"Wu","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104819_b0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2047-783X-16-1-1","article-title":"Update on microbicide research and development \u2013 seeking new HIV prevention tools for women","volume":"16","author":"Mertenskoetter","year":"2011","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.drudis.2026.104819_b0280","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2009.07.022","article-title":"Entry inhibitors in the treatment of HIV-1 infection","volume":"85","author":"Tilton","year":"2010","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2026.104819_b0285","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0140-6736(07)61052-6","article-title":"HIV entry inhibitors","volume":"370","author":"Est\u00e9","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2026.104819_b0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011860","article-title":"The V2 domain of HIV gp120 mimics an interaction between CD4 and integrin \u237a4\u03b27","volume":"19","author":"Van Ryk","year":"2023","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.drudis.2026.104819_b0295","doi-asserted-by":"crossref","first-page":"15812","DOI":"10.1073\/pnas.2634931100","article-title":"Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions","volume":"100","author":"Zhu","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2026.104819_b0300","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/31405","article-title":"Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody","volume":"393","author":"Kwong","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104819_b0305","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1021\/ar4002735","article-title":"Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist","volume":"47","author":"Courter","year":"2014","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.drudis.2026.104819_b0310","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/cbdd.12075","article-title":"Optimization of CD4\/gp120 inhibitors by thermodynamic-guided alanine-scanning mutagenesis","volume":"81","author":"Liu","year":"2013","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.drudis.2026.104819_b0315","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.virol.2005.06.008","article-title":"Identification of N-phenyl-N\u2032-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4","volume":"339","author":"Zhao","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.drudis.2026.104819_b0320","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.str.2008.09.005","article-title":"Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120","volume":"16","author":"Madani","year":"2008","journal-title":"Structure"},{"key":"10.1016\/j.drudis.2026.104819_b0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000360","article-title":"Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state","volume":"5","author":"Haim","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.drudis.2026.104819_b0330","doi-asserted-by":"crossref","first-page":"5478","DOI":"10.1128\/AAC.03339-14","article-title":"Binding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-ray structure and resistance study","volume":"58","author":"Curreli","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2026.104819_b0335","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.2174\/092986710790980005","article-title":"Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown","volume":"17","author":"Reggio","year":"2010","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.drudis.2026.104819_b0340","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/365061a0","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104819_b0345","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1080\/00207454.2016.1257992","article-title":"The central cannabinoid receptor type-2 (CB2) and chronic pain","volume":"127","author":"Shang","year":"2017","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.drudis.2026.104819_b0350","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.tips.2022.06.010","article-title":"Developing the cannabinoid receptor 2 (CB2) pharmacopoeia: past, present, and future","volume":"43","author":"Whiting","year":"2022","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.drudis.2026.104819_b0355","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/aps.2016.149","article-title":"Brain cannabinoid receptor 2: expression, function and modulation","volume":"38","author":"Chen","year":"2017","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.drudis.2026.104819_b0360","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cell.2018.12.011","article-title":"Crystal structure of the human cannabinoid receptor CB2","volume":"176","author":"Li","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2026.104819_b0365","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1021\/acscentsci.3c01461","article-title":"Flipping the GPCR switch: structure-based development of selective cannabinoid receptor 2 inverse agonists","volume":"10","author":"Kosar","year":"2024","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.drudis.2026.104819_b0370","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1038\/s41467-023-37112-9","article-title":"Structural basis of selective cannabinoid CB(2) receptor activation","volume":"14","author":"Li","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104819_b0375","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1002\/chem.201904584","article-title":"Highly selective, amine-derived cannabinoid receptor 2 probes","volume":"26","author":"Westphal","year":"2020","journal-title":"Chemistry"},{"key":"10.1016\/j.drudis.2026.104819_b0380","doi-asserted-by":"crossref","first-page":"8976","DOI":"10.1039\/D6SC00062B","article-title":"Single-position ligand modifications tune CB(2)R activity by targeting the toggle switch","volume":"17","author":"Ganzoni","year":"2026","journal-title":"Chem Sci"},{"key":"10.1016\/j.drudis.2026.104819_b0385","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1359\/jbmr.080420","article-title":"Vitamin D and health: perspectives from mice and man","volume":"23","author":"Bouillon","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.drudis.2026.104819_b0390","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ecl.2017.07.001","article-title":"Biology and mechanisms of action of the vitamin D hormone","volume":"46","author":"Pike","year":"2017","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.drudis.2026.104819_b0395","doi-asserted-by":"crossref","first-page":"7809","DOI":"10.3390\/ijms25147809","article-title":"Vitamin D in central nervous system: implications for neurological disorders","volume":"25","author":"Sailike","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104819_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116744","article-title":"Vitamin D and autoimmune diseases","volume":"233","author":"Illescas-Montes","year":"2019","journal-title":"Life Sci"},{"key":"10.1016\/j.drudis.2026.104819_b0405","article-title":"Impact of vitamin D and vitamin D receptor activator in diabetic nephropathy","volume":"6","author":"Emini","year":"2025","journal-title":"Front Clin Diabetes Healthc"},{"key":"10.1016\/j.drudis.2026.104819_b0410","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nrd3318","article-title":"Vitamin D, disease and therapeutic opportunities","volume":"9","author":"Plum","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104819_b0415","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.abb.2006.11.026","article-title":"Identification of a highly potent vitamin D receptor antagonist: (25S)-26-adamantyl-25-hydroxy-2-methylene-22,23-didehydro-19,27-dinor-20-epi-vitamin D3 (ADMI3)","volume":"460","author":"Igarashi","year":"2007","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.drudis.2026.104819_b0420","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jsbmb.2004.03.046","article-title":"Synthesis and structure-activity relationships of TEI-9647 derivatives as Vitamin D3 antagonists","volume":"89\u201390","author":"Takenouchi","year":"2004","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.drudis.2026.104819_b0425","doi-asserted-by":"crossref","first-page":"6854","DOI":"10.1021\/acs.jmedchem.9b00208","article-title":"Vitamin D and its synthetic analogs","volume":"62","author":"Maestro","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104819_b0430","doi-asserted-by":"crossref","first-page":"9457","DOI":"10.1021\/acs.jmedchem.0c00656","article-title":"Structural analysis of VDR complex with ZK168281 antagonist","volume":"63","author":"Belorusova","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104819_b0435","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1021\/jm8004477","article-title":"Crystal structures of rat vitamin D receptor bound to adamantyl vitamin D analogs: structural basis for vitamin D receptor antagonism and partial agonism","volume":"51","author":"Nakabayashi","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104819_b0440","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2174\/156802606777864881","article-title":"Ligand recognition by vitamin D receptor: Total alanine scanning mutational analysis of the residues lining the ligand binding pocket of vitamin D receptor","volume":"6","author":"Yamada","year":"2006","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.drudis.2026.104819_b0445","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.tins.2006.09.004","article-title":"Targeting adenosine A2A receptors in Parkinson's disease","volume":"29","author":"Schwarzschild","year":"2006","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.drudis.2026.104819_b0450","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.2174\/1381612825666190717105834","article-title":"Therapeutic potentials of A2B adenosine receptor ligands: current status and perspectives","volume":"25","author":"Chandrasekaran","year":"2019","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.drudis.2026.104819_b0455","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.csbj.2015.03.008","article-title":"A2aR antagonists: next generation checkpoint blockade for cancer immunotherapy","volume":"13","author":"Leone","year":"2015","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.drudis.2026.104819_b0460","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fphar.2017.00888","article-title":"Inhibition of A(2A) adenosine receptor signaling in cancer cells proliferation by the novel antagonist TP455","volume":"8","author":"Gessi","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2026.104819_b0465","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1021\/jm4011669","article-title":"Adenosine A2A receptor as a drug discovery target","volume":"57","author":"de Lera","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104819_b0470","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0022-3565(25)12287-8","article-title":"The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist","volume":"276","author":"Zocchi","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2026.104819_b0475","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/j.1476-5381.1995.tb15923.x","article-title":"The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2a selective adenosine receptor antagonist","volume":"115","author":"Poucher","year":"1995","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.drudis.2026.104819_b0480","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0968-0896(98)00025-X","article-title":"8-(Sulfostyryl)xanthines: water-soluble A2A-selective adenosine receptor antagonists","volume":"6","author":"M\u00fcller","year":"1998","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2026.104819_b0485","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1126\/science.1164772","article-title":"The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist","volume":"322","author":"Jaakola","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104819_b0490","doi-asserted-by":"crossref","first-page":"11648","DOI":"10.1021\/acs.jmedchem.2c00462","article-title":"GPCR agonist-to-antagonist conversion: enabling the design of nucleoside functional switches for the A(2A) adenosine receptor","volume":"65","author":"Shiriaeva","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104819_b0495","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1021\/jm201229j","article-title":"Structure-activity relationships of truncated C2- or C8-substituted adenosine derivatives as dual acting A2A and A3 adenosine receptor ligands","volume":"55","author":"Hou","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104819_b0500","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1158\/1055-9965.1558.13.10","article-title":"Etiology of hormone receptor-defined breast cancer: a systematic review of the literature","volume":"13","author":"Althuis","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.drudis.2026.104819_b0505","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/978-3-031-11836-4_10","article-title":"Estrogen receptor alpha and ESR1 mutations in breast cancer","volume":"1390","author":"Patel","year":"2022","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.drudis.2026.104819_b0510","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1021\/jm970019l","article-title":"Steroidal affinity labels of the estrogen receptor. 3. Estradiol 11 beta-n-alkyl derivatives bearing a terminal electrophilic group: antiestrogenic and cytotoxic properties","volume":"40","author":"Lobaccaro","year":"1997","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104819_b0515","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1021\/jm990179s","article-title":"Steroidal affinity labels of the estrogen receptor alpha. 4. Electrophilic 11beta-aryl derivatives of estradiol","volume":"43","author":"Aliau","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104819_b0520","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jsbmb.2005.09.006","article-title":"Identification of covalent attachment site of antiestrogenic estradiol 11 beta-derivatives on human estrogen receptor alpha ligand-binding domain","volume":"98","author":"Aliau","year":"2006","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.drudis.2026.104819_b0525","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1016\/j.bmc.2012.04.041","article-title":"Synthesis and evaluation of 11\u03b2-(4-substituted phenyl) estradiol analogs: transition from estrogen receptor agonists to antagonists","volume":"20","author":"Hanson","year":"2012","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2026.104819_b0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.sbi.2023.102574","article-title":"New insights into GPCR coupling and dimerisation from cryo-EM structures","volume":"80","author":"Gusach","year":"2023","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.drudis.2026.104819_b0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2023.102427","article-title":"AI-driven GPCR analysis, engineering, and targeting","volume":"74","author":"Velloso","year":"2024","journal-title":"Curr Opin Pharmacol"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:36:45Z","timestamp":1791661005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626002242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":107,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1359644626002242"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104819","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Agonist-informed antagonist discovery: Discovery approaches, medicinal chemistry insights, and design boundaries","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104819","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104819"}}